Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017601 · ClinicalTrials.gov registry record · Phase 2
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01017601 is a Phase 2 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 59 participants.
The verdict
NCT01017601, a Phase 2 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
RATIONALE: A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells. It is not yet known whether NTX-010 is more effective than a placebo in treating small cell lung cancer. PURPOSE: This randomized phase II trial is studying NTX-010 to see how well it works compared with a placebo when given after chemotherapy in treating patients with extensive-stage small cell lung cancer.
Interventions
- OTHER placebo
- BIOLOGICAL Seneca Valley virus-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017601
The ClinicalTrials.gov registry entry for NCT01017601 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01017601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01017601 about?
NCT01017601 is a clinical study titled "Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer". RATIONALE: A virus called Seneca Valley virus-001 (NTX-010) may be able to kill tumor cells without damaging normal cells. It is not yet known whether NTX-010 is more effective than a placebo in treating small cell lung cancer. PURPOSE: This randomized phase II trial is studying NTX-010 to see how ...
What is the current status of trial NCT01017601?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2010-01. Estimated completion is 2014-11-15.
What interventions are being tested in trial NCT01017601?
The interventions under investigation include: placebo (OTHER), Seneca Valley virus-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01017601?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.